Cancer Treatment Prognostic


Breast cancer and ovarian cancer prognosis still have high number of deaths in developed countries mainly due to cancer survival after disease treatment. Prediction of clinical response to treatment and patient selection for a therapy with adequate chemotherapy helps to increase overall quality of life and survival. We have found a novel biomarker of tumour aggressiveness (code: C53) with prog­nostic value for breast and ovarian cancer and defined targets for potential selective treatment.

Low expression of C53 in breast and ovarian tumours strongly associates with lower overall and relapse-free survival outcomes, particularly relevant for basal breast tumours related to BRCA2. Results come from the study of comparing tumours data over 3.500 breast cancer patients (BRCA2) treated and over 300 high grade serous ovarian cancer patients treated. Therefore, C53 downregulation leads to the worse possible scenario for tumour progression, because it confers genome instability as well as resistance to conventional chemotherapy.